139 related articles for article (PubMed ID: 22438049)
1. Accuracy of BRCA1/2 mutation prediction models in Korean breast cancer patients.
Kang E; Park SK; Yang JJ; Park B; Lee MH; Lee JW; Suh YJ; Lee JE; Kim HA; Oh SJ; Kim SW;
Breast Cancer Res Treat; 2012 Aug; 134(3):1189-97. PubMed ID: 22438049
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
Eoh KJ; Park JS; Park HS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
Gynecol Oncol; 2017 Apr; 145(1):137-141. PubMed ID: 28159408
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients.
Rao NY; Hu Z; Yu JM; Li WF; Zhang B; Su FX; Wu J; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 Aug; 116(3):563-70. PubMed ID: 18807178
[TBL] [Abstract][Full Text] [Related]
4. Evaluating BRCA mutation risk predictive models in a Chinese cohort in Taiwan.
Hung FH; Wang YA; Jian JW; Peng HP; Hsieh LL; Hung CF; Yang MM; Yang AS
Sci Rep; 2019 Jul; 9(1):10229. PubMed ID: 31308460
[TBL] [Abstract][Full Text] [Related]
5. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
Euhus DM; Smith KC; Robinson L; Stucky A; Olopade OI; Cummings S; Garber JE; Chittenden A; Mills GB; Rieger P; Esserman L; Crawford B; Hughes KS; Roche CA; Ganz PA; Seldon J; Fabian CJ; Klemp J; Tomlinson G
J Natl Cancer Inst; 2002 Jun; 94(11):844-51. PubMed ID: 12048272
[TBL] [Abstract][Full Text] [Related]
6. Performance of BRCA1/2 mutation prediction models in Asian Americans.
Kurian AW; Gong GD; Chun NM; Mills MA; Staton AD; Kingham KE; Crawford BB; Lee R; Chan S; Donlon SS; Ridge Y; Panabaker K; West DW; Whittemore AS; Ford JM
J Clin Oncol; 2008 Oct; 26(29):4752-8. PubMed ID: 18779604
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort.
Kwong A; Wong CH; Suen DT; Co M; Kurian AW; West DW; Ford JM
World J Surg; 2012 Apr; 36(4):702-13. PubMed ID: 22290208
[TBL] [Abstract][Full Text] [Related]
8. Assessing BRCA carrier probabilities in extended families.
Barcenas CH; Hosain GM; Arun B; Zong J; Zhou X; Chen J; Cortada JM; Mills GB; Tomlinson GE; Miller AR; Strong LC; Amos CI
J Clin Oncol; 2006 Jan; 24(3):354-60. PubMed ID: 16421416
[TBL] [Abstract][Full Text] [Related]
9. Performance of BRCA1/2 mutation prediction models in male breast cancer patients.
Moghadasi S; Grundeken V; Janssen LAM; Dijkstra NH; Rodríguez-Girondo M; van Zelst-Stams WAG; Oosterwijk JC; Ausems MGEM; Oldenburg RA; Adank MA; Blom EW; Ruijs MWG; van Os TAM; van Deurzen CHM; Martens JWM; Schroder CP; Wijnen JT; Vreeswijk MPG; van Asperen CJ
Clin Genet; 2018 Jan; 93(1):52-59. PubMed ID: 28589637
[TBL] [Abstract][Full Text] [Related]
10. KOHBRA BRCA risk calculator (KOHCal): a model for predicting BRCA1 and BRCA2 mutations in Korean breast cancer patients.
Kang E; Park SK; Lee JW; Kim Z; Noh WC; Jung Y; Yang JH; Jung SH; Kim SW
J Hum Genet; 2016 May; 61(5):365-71. PubMed ID: 26763880
[TBL] [Abstract][Full Text] [Related]
11. Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detection.
van Harssel JJ; van Roozendaal CE; Detisch Y; Brandão RD; Paulussen AD; Zeegers M; Blok MJ; Gómez García EB
Fam Cancer; 2010 Jun; 9(2):193-201. PubMed ID: 19949876
[TBL] [Abstract][Full Text] [Related]
12. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
Antoniou AC; Hardy R; Walker L; Evans DG; Shenton A; Eeles R; Shanley S; Pichert G; Izatt L; Rose S; Douglas F; Eccles D; Morrison PJ; Scott J; Zimmern RL; Easton DF; Pharoah PD
J Med Genet; 2008 Jul; 45(7):425-31. PubMed ID: 18413374
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: the Korean Hereditary Breast Cancer (KOHBRA) Study.
Son BH; Ahn SH; Kim SW; Kang E; Park SK; Lee MH; Noh WC; Kim LS; Jung Y; Kim KS; Noh DY; Moon BI; Suh YJ; Lee JE; Choi DH; Kim SY; Jung SH; Yom CK; Lee H; Yang JH;
Breast Cancer Res Treat; 2012 Jun; 133(3):1143-52. PubMed ID: 22382806
[TBL] [Abstract][Full Text] [Related]
14. The prevalence of BRCA mutations among familial breast cancer patients in Korea: results of the Korean Hereditary Breast Cancer study.
Han SA; Kim SW; Kang E; Park SK; Ahn SH; Lee MH; Nam SJ; Han W; Bae YT; Kim HA; Cho YU; Chang MC; Paik NS; Hwang KT; Kim SJ; Noh DY; Choi DH; Noh WC; Kim LS; Kim KS; Suh YJ; Lee JE; Jung Y; Moon BI; Yang JH; Son BH; Yom CK; Kim SY; Lee H; Jung SH;
Fam Cancer; 2013 Mar; 12(1):75-81. PubMed ID: 23131904
[TBL] [Abstract][Full Text] [Related]
15. Selecting a BRCA risk assessment model for use in a familial cancer clinic.
Panchal SM; Ennis M; Canon S; Bordeleau LJ
BMC Med Genet; 2008 Dec; 9():116. PubMed ID: 19102775
[TBL] [Abstract][Full Text] [Related]
16. Comparison between CaGene 5.1 and 6.0 for BRCA1/2 mutation prediction: a retrospective study of 150 BRCA1/2 genetic tests in 517 families with breast/ovarian cancer.
Antonucci I; Provenzano M; Sorino L; Balsamo M; Aceto GM; Battista P; Euhus D; Cianchetti E; Ballerini P; Natoli C; Palka G; Stuppia L
J Hum Genet; 2017 Mar; 62(3):379-387. PubMed ID: 27928164
[TBL] [Abstract][Full Text] [Related]
17. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
[TBL] [Abstract][Full Text] [Related]
18. 10-year performance of four models of breast cancer risk: a validation study.
Terry MB; Liao Y; Whittemore AS; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Chung WK; Knight JA; Southey MC; Milne RL; Goldgar D; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; John EM; Phillips KA; Daly MB; Buys SS; Hopper JL; MacInnis RJ
Lancet Oncol; 2019 Apr; 20(4):504-517. PubMed ID: 30799262
[TBL] [Abstract][Full Text] [Related]
19. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
[TBL] [Abstract][Full Text] [Related]
20. Limited family structure and BRCA gene mutation status in single cases of breast cancer.
Weitzel JN; Lagos VI; Cullinane CA; Gambol PJ; Culver JO; Blazer KR; Palomares MR; Lowstuter KJ; MacDonald DJ
JAMA; 2007 Jun; 297(23):2587-95. PubMed ID: 17579227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
